Clinical Trial Update: Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating WP1302 to prevent relapse after methimazole withdrawal in Graves' disease is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Disease

Drugs mentioned

• WP1302

Snippet

Sponsor: Worg Biotherapeutics Inc. | Conditions: Graves Disease | Phase 2 | Status: SUSPENDED